C
위더스제약
330350KOSDAQ의약품 제조업50.5 / 100
Reference Date: 2026-04-13
Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly up 1.7% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Widus Pharmaceutical is a pharmaceutical company specializing in finished drug products for chronic diseases, focusing on cardiovascular, musculoskeletal, and digestive system treatments. Its key revenue driver is Atoren, a generic version of Lipitor, accounting for about 30% of total sales. The company is expanding its CMO business and enhancing market share through new product development.
Number of Employees
220people
Average Salary
52.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
22.73Industry Average 14.801.5Point
1.5x industry avg (risky)
PBR
1.15Industry Average 1.042.5Point
Higher than industry avg (caution)
ROE
5.20Industry Average 4.424.0Point
In line with industry avg
Debt Ratio
5.90Industry Average 11.986.5Point
Half of industry avg (excellent)
Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲15.9% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼14.2% (2-year basis)
ROE Trend
2.0 / 4
Avg ROE 6.5% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (39%)
Current 8,550Won52-week high 11,94052-week low 6,300
1-month return3.0Point
1m 1.66% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral정기주주총회결과2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral감사보고서제출2026-03-18